⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 22, 2024Open Access

Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Alexandria P. Eiken Audrey L. Smith Sydney A. Skupa Elizabeth Schmitz Sandeep Rana Sarbjit Singh Siddhartha Kumar Jayapal Reddy Mallareddy Aguirre A. de Cubas Akshay Krishna Achyuth Kalluchi M. Jordan Rowley Christopher R. D’Angelo Matthew A. Lunning R. Gregory Bociek Julie M. Vose Amarnath Natarajan Dalia El‐Gamal

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S4 shows SpiD3 inhibits CLL chemotaxis and induces transcription of UPR genes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eiken et al. (2024) studied this question.

synapsesocial.com/papers/68e68fb4b6db643587616aec https://doi.org/10.1158/2767-9764.25880270.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
2Figure S6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
3Figure S8 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
4Figure S3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024
5Figure S7 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024